Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  AML NHL Hodgkin Disease All Myelodysplastic Syndrome Voluntary written informed consent Patients who are considered for allogeneic transplantation based on their disease risk (see below) but lack matched sibling or unrelated donors or who are unable to proceed to allogeneic transplant within 8 weeks, will be considered for UCB transplantation on this study. Only patients for whom RIC will be considered are eligible. RIC is considered in those older than 45 or younger than 45 with Hematopoietic Cell Transplant (HCT) Comorbidity Index of 3 or higher (HCT) Comorbidity Index can be calculated using the following link: http://www.hctci.org/Home/Calculator Patients with acute myeloid leukemia (AML) in CR1 that is not considered favorable-risk (favorable risk is defined as patients with t(15;17)(q22;q21), t(8;21)(q22;q22), inv(16)(p13q22)/t(16;16)(p13;q22), NPM1 mutation without FLT3-ITD, and double-mutated CEBPA58,59), AML in CR2 or subsequent CR, high-risk acute lymphoblastic leukemia (ALL) in CR1, or ALL in CR2 or higher, biphenotypic leukemia defined as coexpression of B-lymphoid and myeloid markers or T-lymphoid and myeloid markers in the blast population60or undifferentiated leukemia in ≥CR1. Myelodysplatic syndrome (MDS)/myeloproliferative neoplasm (MPN) patients with less than 10% bone marrow blasts and no peripheral blood blasts on pre-transplant bone marrow aspirate/biopsy are considered for FluCyTTBI regimen. Chemotherapy sensitive (achievement of at least a partial response according to Lugano classification61) Hodgkin's disease (HD) that relapsed following high-dose therapy. Chemotherapy sensitive (achievement of at least a partial response according to Lugano classification) non-Hodgkin's lymphoma (NHL) patients who relapsed post-high-dose therapy and autologous transplantation. Subjects should be enrolled within 30 days of transplant For ALL, high-risk features are defined using modified Hoelzer risk criteria62, these are: 1. High white blood cell count at diagnosis (ie, >30,000/microL in B-ALL or >100,000/microL in T-ALL). 2. Clonal cytogenetic abnormalities t(4;11), t(1;19), t(9;22), or BCR-ABL gene positivity. 3. Progenitor-B cell immunophenotype (eg, blasts expressing membrane CD19, CD79a, and cytoplasmic CD22). 4. Length of time from start of induction therapy to attainment of CR greater than four weeks. 5. Older age >60 years old is high risk, 30 to 59 years old is intermediate risk. 6. MRD a post-remission bone marrow MRD level ≥10-3 by molecular tests Subjects must be ≥ 18 years old and ≤ 70 years old Karnofsky performance status (KPS) of ≥ 70% (Appendix A) Adequate hepatic, renal, cardiac and pulmonary function to be eligible for transplant. Minimum  Pregnant or breastfeeding Severe chronic obstructive pulmonary disease requiring oxygen supplementation History of spontaneous pneumothorax Active ear/sinus infection. Patients with chronic sinusitis or sinus headaches are excluded unless cleared by ear, nose, throat provider Evidence of pneumothorax or significant pulmonary fibrosis on chest imaging within 60 days of transplant Prior chest surgery requiring thoracotomy or direct chest irradiation Recent of sinus or ear surgery, excluding myringotomy or ear tubes (within the last 5 years) Claustrophobia Patients who had intrathecal chemotherapy within 2 weeks of starting preparative regimen or cranial irradiation within 4 weeks of starting preparative regimen History of seizures